Pharmaceutical agent for inducing specific immunity against sars-cov-2

A pharmaceutical agent for the induction of specific immunity against severe acute respiratory syndrome virus (SARS-CoV-2), comprising:

• component 1, comprising:
• an expression vector composition, comprising:
• a genome of recombinant human adenovirus serotype 26, wherein the E1 and E3 regions are deleted from the genome and the ORF6-Ad26 region is replaced by ORF6-Ad5 with an expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3;
• and
• component 2, comprising:
• an expression vector composition, comprising:
• a genome of recombinant simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted from the genome with an expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3.

A pharmaceutical agent for the induction of specific immunity against severe acute respiratory syndrome virus (SARS-CoV-2), comprising:

• component 1, comprising:
• an expression vector composition, comprising:
• a genome of recombinant simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted from the genome with an expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3:
• and
• component 2, comprising:
• an expression vector composition, comprising:
• a genome of recombinant human adenovirus serotype 5, wherein the E1 and E3 regions are deleted from the genome with an expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.